Denali Secures $500M in Financing, Focuses on Large Molecule Biotherapeutics

Some existing investors are pumping $500 million into Denali Therapeutics to help support ongoing research and development activities, including its blood-brain barrier crossing therapeutics. The biotech announced the sale of more of its shares through a private investment in public equity financing Tuesday.